The FDA approved Lipfendra, a new drug for adults with high LDL cholesterol, as the first PCSK9 inhibitor available as a once ...
A significant breakthrough in heart disease prevention arrived on July 16, 2026, with the FDA approval of Lipfendra ...
Lipfendra, the first once-daily oral PCSK9 inhibitor, was shown to reduce LDL cholesterol by roughly 56% to 60% when combined ...
The drug from Merck was OK'd for patients with artery-clogging cholesterol that persists even after taking statins.
Patients who need to lower their cholesterol will soon have a powerful new option. On Thursday, the Food and Drug ...
A high fasting cholesterol reading ---especially elevated LDL (low-density lipoprotein), often called the "bad" cholesterol - ...
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough ...
More than half of US adults are eligible for primary prevention with statins, yet lipid-lowering therapies remain underused.
On Thursday, July 16, the FDA approved Lipfendra, a once-daily cholesterol-lowering medication from Merck. According to a ...
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase ...
You might have high LDL cholesterol and not even know it. We spoke to experts about how to monitor this health stat so you ...
The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results